{
  "@context": {
    "nccn": "http://nccn-guideline.org/vocab#",
    "xsd": "http://www.w3.org/2001/XMLSchema#",
    "nccn:next": {
      "@type": "@id"
    },
    "nccn:prev": {
      "@type": "@id"
    },
	"nccn:contains": {
	 "@type":"@id"
	},
	"nccn:reference": {
	 "@type":"@id"
	}
  },
  "@graph": [
    {
      "@id": "http://nccn-guideline.org/vocab/0",
      "@type": "nccn:CLINICAL ASSESSMENT",
      "nccn:content": "Stage IIIB (T1–2, N3)Stage IIIC (T3, N3)",
      "nccn:prev": [],
      "nccn:next": [
        "http://nccn-guideline.org/vocab/1"
      ]
    },
    {
      "@id": "http://nccn-guideline.org/vocab/1",
      "@type": "nccn:PRETREATMENT EVALUATION",
      "nccn:contains": ["http://nccn-guideline.org/vocab/1a","http://nccn-guideline.org/vocab/1b","http://nccn-guideline.org/vocab/1c","http://nccn-guideline.org/vocab/1d"],
      "nccn:prev": [
        "http://nccn-guideline.org/vocab/0"
      ],
      "nccn:next": ["http://nccn-guideline.org/vocab/2","http://nccn-guideline.org/vocab/3","http://nccn-guideline.org/vocab/4"]
    },
    {
      "@id": "http://nccn-guideline.org/vocab/2",
      "@type": "nccn:PRETREATMENT EVALUATION",
      "nccn:content": "N3 negative",
      "nccn:prev": [
        "http://nccn-guideline.org/vocab/1"
      ],
      "nccn:next": ["http://nccn-guideline.org/vocab/5"]
    },
	{
      "@id": "http://nccn-guideline.org/vocab/3",
      "@type": "nccn:PRETREATMENT EVALUATION",
      "nccn:content": "N3 positive",
      "nccn:prev": [
        "http://nccn-guideline.org/vocab/1"
      ],
      "nccn:next": ["http://nccn-guideline.org/vocab/6"]
    },
	{
      "@id": "http://nccn-guideline.org/vocab/4",
      "@type": "nccn:PRETREATMENT EVALUATION",
      "nccn:content": "Metastatic disease",
      "nccn:prev": [
        "http://nccn-guideline.org/vocab/1"
      ],
      "nccn:next": ["http://nccn-guideline.org/vocab/7"]
    },
	{
      "@id": "http://nccn-guideline.org/vocab/5",
      "@type": "nccn:INITIAL TREATMENT",
      "nccn:content": "Initial treatment for stage I–IIIA (NSCL-9)",
      "nccn:prev": [
        "http://nccn-guideline.org/vocab/2"
      ],
      "nccn:next": []
    },
	{
      "@id": "http://nccn-guideline.org/vocab/6",
      "@type": "nccn:INITIAL TREATMENT",
      "nccn:content": "Definitive concurrent chemoradiation{l},{t} (category 1)",
      "nccn:prev": [
        "http://nccn-guideline.org/vocab/3"
      ],
      "nccn:next": ["http://nccn-guideline.org/vocab/9"],
	  "nccn:reference": ["http://nccn-guideline.org/vocab/l","http://nccn-guideline.org/vocab/t"]
    },
	{
      "@id": "http://nccn-guideline.org/vocab/7",
      "@type": "nccn:INITIAL TREATMENT",
      "nccn:content": "Treatment for Metastasis limited sites (NSCL-14) or distant disease (NSCL-17)",
      "nccn:prev": [
        "http://nccn-guideline.org/vocab/4"
      ],
      "nccn:next": []
    },
	{
      "@id": "http://nccn-guideline.org/vocab/8",
      "@type": "nccn:INITIAL TREATMENT",
      "nccn:content": "Surveillance (NSCL-16)",
      "nccn:prev": [
        "http://nccn-guideline.org/vocab/9"
      ],
      "nccn:next": []
    },
	{
      "@id": "http://nccn-guideline.org/vocab/9",
      "@type": "nccn:INITIAL TREATMENT",
      "nccn:content": "Durvalumab{t},{u} (category 1)",
      "nccn:prev": [
        "http://nccn-guideline.org/vocab/6"
      ],
      "nccn:next": ["http://nccn-guideline.org/vocab/8"],
	  "nccn:reference": ["http://nccn-guideline.org/vocab/t","http://nccn-guideline.org/vocab/u"]
    },
	{
      "@id": "http://nccn-guideline.org/vocab/j",
      "@type": "nccn:Footnote",
      "nccn:content": "PET/CT performed skull base to knees or whole body. Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation."
      
    },
	{
      "@id": "http://nccn-guideline.org/vocab/l",
      "@type": "nccn:Footnote",
      "nccn:content": "Principles of Radiation Therapy (NSCL-C)."
      
    },
	{
      "@id": "http://nccn-guideline.org/vocab/o",
      "@type": "nccn:Footnote",
      "nccn:content": "If MRI is not possible, CT of head with contrast."
      
    },
	{
      "@id": "http://nccn-guideline.org/vocab/t",
      "@type": "nccn:Footnote",
      "nccn:content": "Concurrent Chemoradiation Regimens (NSCL-F)."
      
    },
	{
      "@id": "http://nccn-guideline.org/vocab/u",
      "@type": "nccn:Footnote",
      "nccn:content": "Durvalumab is not recommended for patients following definitive surgical resection."
      
    },
	{
      "@id": "http://nccn-guideline.org/vocab/1a",
      "@type": "nccn:PRETREATMENT EVALUATION",
      "nccn:content": "PFTs (if not previously done)"
       
    },
	{
      "@id": "http://nccn-guideline.org/vocab/1b",
      "@type": "nccn:PRETREATMENT EVALUATION",
      "nccn:content": "FDG PET/CT scan{j} (if not previously done)",
      "nccn:reference": "http://nccn-guideline.org/vocab/j"
    },
	{
      "@id": "http://nccn-guideline.org/vocab/1c",
      "@type": "nccn:PRETREATMENT EVALUATION",
      "nccn:content": "Brain MRI with contrast{o}",
      "nccn:reference": "http://nccn-guideline.org/vocab/o"
    },
	{
      "@id": "http://nccn-guideline.org/vocab/1d",
      "@type": "nccn:PRETREATMENT EVALUATION",
      "nccn:content": "Pathologic confirmation of N3 disease by:\u0017Mediastinoscopy\u0017Supraclavicular lymph node biopsy \u0017Thoracoscopy \u0017Needle biopsy \u0017Mediastinotomy \u0017EUS biopsy\u0017EBUS biopsy"
      
    }
  ]
}